On November 11, 2021, Ignis Therapeutics, a biopharmaceutical company focusing on the central nervous system (CNS) incubated by 6 Dimensions Capital (6D), a Shanghai-based global investment firm, announced its $180 million Series A financing led by 6D. To date, the transaction represents the largest Series A financing in the biopharmaceutical sector in China in 2021. The financing includes co-investor participation by Ruentex Group, KB Investment, WTT investment, Mubadala Investment Company, HBM Healthcare Investments, and Goldman Sachs.

As part of the transaction, Ignis Therapeutics enters into a long-term strategic license agreement with SK Biopharmaceuticals (SKBP) under which SKBP out-licenses six of its clinical compounds, including U.S. FDA-approved cenobamate and solriamfetol, to Ignis Therapeutics, for development and commercialization. The proceeds from the Series A round of financing will be used for development and commercialization of these products. 

Wilson Sonsini Goodrich & Rosati represented 6D and Ignis Therapeutics in this transaction. The team includes:

Corporate
Weiheng Chen, Partner
Jie Zhu, Partner
Can Yin, Of Counsel
Xuchao Dong, Of Counsel

Patents and Innovations
Chi-Fei Wang, Of Counsel
Richard Wang, Of Counsel

For more information, please see SKBP’s press release.